Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 30, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - May 30, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/29/16 - "System and Method for Dilating and Adjusting Flexibility in a Guiding Device" in Patent Application Approval Process (USPTO 20160120567)
By a News Reporter-Staff News Editor at Heart Disease Weekly A patent application by the inventor Wilkinson, Matthew, filed on August 3, 2015, was made available online on May 12, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Cordis Corporation. The following
5/29/16 - Boehringer expects UAE sales growth to reach double digits [National, The (United Arab Emirates)]
Boehringer Ingelheim, a German pharmaceutical company, expects to post double-digit sales growth in the UAE on the back of new product launches this year, according to a top official. Last year the company reported annual UAE sales growth of 34 per cent and 26 per cent across the wider Mena region. Consultants Euromonitor International believe the
5/29/16 - Changing default prescription settings in EMRs increased rates of generic drugs, Penn Medicine study finds
By a News Reporter-Staff News Editor at VerticalNews Health PHILADELPHIA Using generic instead of brand name medications can save money for both patients and health systems. A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania, found that a simple change to prescription default options in electronic
5/29/16 - Congestive Heart Failure Heart Failure Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Novartis,...
Congestive Heart Failure Heart Failure Global Clinical Trials Review, H1, 2016- Analysis, Technologies& Forecasts- Key Vendors: Novartis, Johnson& Johnson, Bayer- Research and Markets. By a News Reporter-Staff News Editor at Heart Disease Weekly Research and Markets has announced the addition of the "Congestive Heart Failure Global Clinical Trial
5/29/16 - Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial and First Quarter 2016 Financial...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex , a novel, broad-spectrum, topical antibiotic peptide, announced that it has completed the patient enrollment objective in the OneStep-2 pivotal Ph
5/29/16 - H3 Biomedicine Receives FDA Acceptance for Investigational New Drug Application
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of the Eisai Group, announced that the U.S. Food and Drug Administration accepted the company's Investigational New Drug application
5/29/16 - IDELVION CSL Behring's Innovative Therapy for Hemophilia B Patients Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA CSL Behring announced it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration for IDELVION. The FDA grants marketing exclusivity for innovative, first-to-market orphan drugs, such as IDELVION. IDELVION was approved by the FDA in March
5/29/16 - Integral BioSystems Presenting Innovative NanoM? Platform-based Ocular Pipeline at MALSI on June 2nd 2016 in Boston, MA
Integral developing NanoM? platform for extended release, preservative-free, and self-administered treatment of glaucoma and inflammation post-cataract surgery.. BEDFORD, MASSACHUSETTS, USA, May 28, 2016/ EINPresswire.com/ BEDFORD, MASSACHUSETTS, USA, May 28, 2016 Integral BioSystems LLC, Boston area drug development CRO specializing in pharm
5/29/16 - Study: Medicare Part D boosts medication adherence, reduces blood pressure risk
By a News Reporter-Staff News Editor at VerticalNews Health& Science New research from North Carolina State University shows that implementation of Medicare Part D has increased the number of people taking their prescribed medications as directed- so-called "medication adherence"- and reduced the likelihood that newly covered beneficiaries develo
5/29/16 - Sun Pharma gets summons from U.S. Justice Department over drug prices [Big News Network (United Arab Emirates)]
WASHINGTON, U.S. U.S. Department of Justice has reportedly delivered summons to Sun Pharmaceutical Industries' U.S. wing to furnish the department with the prices and marketing of its generic drugs sold in the U.S.. It was added that the summons were in line with the U.S. investigation into generic drug pricing, jump started by Senator Bernie Sa
5/29/16 - Supply of standard generic medicine for cantonment general hospital [TendersInfo (India)]
Tenders are invited for Supply of standard generic medicine for cantonment general hospital, clement town dehradun for the year 2016-17 from C&F, Super distributor or authorized medical distributor of pharmaceutical companies FDR: Rs. 10,000/- Tender form cost: Rs. 500/-+ 13.5% VAT Last date: 22/06/2016 Major organization: CANTONMENT BOARD Address:
5/28/16 - "Use of a Thiazolo Pyrimidinone for the Treatment of Inflammatory Bowel Disease" in Patent Application Approval Process (USPTO 20160120801)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors DUTT, Chaitanya; CHAUTHAIWALE, Vijay; GUPTA, Ram; ZAMBAD, Shitalkumar; DESHPANDE, Shailesh; KOTECHA, Jignesh; GUPTA, Ramesh; SRIVASTAVA, Sanjay; CHHIPA, Laxmikant; ABRAHAM, Jaya, filed on May 12, 2014, was made available online on May 12,
5/28/16 - AbbVie, Biogen: FDA Approves Once-Monthly ZINBRYTA For Multiple Sclerosis
WESTON- AbbVie, a research-based biopharmaceutical company, and Biogen late Friday announced that the U.S. Food and Drug Administration or FDA approved ZINBRYTA, a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis or RMS. The FDA approval of ZINBRYTA is primarily based on results from two clinical
5/28/16 - ASTRAZENECA'S FASLODEX MET PRIMARY ENDPOINT IN FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER [tayyar.org (Lebanon)]
-AstraZeneca today announced positive results from the Phase III FALCON trial. Sean Bohen, Executive Vice President, Global Medicines Development and Chief. Medical Officer at AstraZeneca, said: "The FALCON results bring us closer to.
5/28/16 - BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS in the U.S.
By a News Reporter-Staff News Editor at Marketing Weekly News BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS in the U.S. to Collegium. Under terms of the agreement, Collegium will be...
5/28/16 - Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA? (Daclizumab) for Multiple Sclerosis
CAMBRIDGE, Mass.& NORTH CHICAGO, Ill. The U.S. Food and Drug Administration approved ZINBRYTA TM, a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis, Biogen and AbbVie announced today. Clinical data showed ZINBRYTA significantly reduced relapses and brain lesions for up to three years compare
5/28/16 - Cyclacel Announces Reverse Stock Split [Cihan News Agency (Turkey)]
-Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that effective at 5:00 p.m., Eastern Time, on May 27, 2016, the Company will effect a one-for-twelve reverse stock split of its outstandi
5/28/16 - Eagle Pharmaceuticals Inc is a Sell; Strong Momentum from Option Traders [Qatar Tribune]
In todays session Eagle Pharmaceuticals Inc recorded an unusually high contracts volume of put trades. The stock decreased 4.98% or $2.44 during the last trading session, hitting $46.55. Eagle Pharmaceuticals Inc has declined 28.55% since October 21, 2015 and is downtrending.
5/28/16 - Egypt Sets Ceiling for Drug Price Increase at EGP 6 per pack [Middle East Business News]
Egypt imposed a EGP 6 ceiling per pack on the increase in the price of medicines, after a number of pharmacists and drug companies circumvented an earlier decision to raise fixed prices, MENA agency quoted health minister Ahmed Emad Eddin said.. Egypt increased the price of medicines under EGP 30 by 20 percent in an effort to tackle a shortage in s
5/28/16 - FDA approves CSL Behring's single-chain Afstyla for hemophilia A [Palestine Chronicle, The]
The US Food and Drug Administration has approved CSL Behring's Afstyla to treat adults and children with hemophilia A. CSL Behring's license applications for Afstyla are being reviewed by regulatory agencies in Europe, Switzerland and Australia. The US Centers for Disease Control and Prevention estimates that the condition affects about one in 6,00
5/28/16 - FDA Grants Accelerated Approval to Ocaliva? (Obeticholic Acid) for the Treatment of Patients with PBC
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the U.S. Food and Drug Administration has granted accelerated approval to Ocaliva for the treatment of primary biliary cholangitis, previously know
5/28/16 - Generics maker Sawai Pharma prepares to tap US market [Seven Days (United Arab Emirates)]
Sawai Pharmaceutical is gearing up to sell generic drugs in the U.S., carrying out a strategy shift that makes the huge American market a central pillar of the company's long-term growth plans. The U.S. generic-drug market is estimated at $91 billion, 10 times the annual market in Japan. The company intends to formulate pitavastatin and the three o
5/28/16 - Highland Therapeutics Announces Appointment of Craig S. Lewis as President
By a News Reporter-Staff News Editor at Marketing Weekly News Highland Therapeutics Inc. announced that its U.S. subsidiary, Ironshore Pharmaceuticals Inc., has appointed Craig S. Lewis to the position of President, reporting directly to the IPA Board of Directors. Prior to that, Mr. Lewis served as the Senior Vice President, Global Business Insi
5/28/16 - India : Cipla wins regulatory approval to sell its version of Truvada [TendersInfo (India)]
Drugmaker Cipla has won regulatory approval in India for the sale of its version of Truvada as a preventive that healthy people can use to lower their risk of getting HIV. Commonly called PrEP in the healthcare industry, Truvada, sold by US drug manufacturer Gilead, is the sole medicine approved worldwide as a preventive in handling HIV. The recent
5/28/16 - Japan : Chugais Bispecific Antibody ACE910/Emicizumab Phase l Data in Patients with Hemophilia A Published in The New England Journal Of Medicine... [TendersInfo (India)]
Chugai Pharmaceutical Co., Ltd. announced today that the data from hemophilia A patients who participated in a Phase I study of the bispecific antibody emicizumab was published online in The New England Journal of Medicine on May 25, 2016. The study results had been presented at the 56th American Society of Hematology Annual Meeting held in San Fra
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415